Home » Stocks » PRPO

Precipio, Inc. (PRPO)

Stock Price: $2.18 USD -0.05 (-2.24%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $2.27 +0.09 (4.13%) Mar 5, 6:47 PM
Market Cap 37.55M
Revenue (ttm) 4.84M
Net Income (ttm) -15.88M
Shares Out 16.01M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.18
Previous Close $2.23
Change ($) -0.05
Change (%) -2.24%
Day's Open 2.21
Day's Range 1.91 - 2.22
Day's Volume 743,309
52-Week Range 0.55 - 8.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

Company Strengthens Depth of Expertise in Products Industry Company Strengthens Depth of Expertise in Products Industry

GlobeNewsWire - 3 days ago

NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the ...

GlobeNewsWire - 1 month ago

Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC

GlobeNewsWire - 1 month ago

Partnership with ION Solutions expected to accelerate sales Partnership with ION Solutions expected to accelerate sales

GlobeNewsWire - 2 months ago

Thousands of Oncology Practices will gain access to HemeScreen POL program Thousands of Oncology Practices will gain access to HemeScreen POL program

Seeking Alpha - 3 months ago

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST

GlobeNewsWire - 5 months ago

Prominent Laboratories in US and Europe will begin testing the media Prominent Laboratories in US and Europe will begin testing the media

GlobeNewsWire - 5 months ago

Panel of clinically critical genes can yield same-day results outperforming major competitors Panel of clinically critical genes can yield same-day results outperforming major competitors

GlobeNewsWire - 6 months ago

Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy Ilan Danieli, Precipio CEO, will address questions from shareholders related to compan...

GlobeNewsWire - 6 months ago

Partnership is expected to accelerate product introduction to most major labs worldwide Partnership is expected to accelerate product introduction to most major labs worldwide

Seeking Alpha - 6 months ago

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST

GlobeNewsWire - 7 months ago

Test initially offered to Precipio’s customer base, then expanding distribution reach Test initially offered to Precipio’s customer base, then expanding distribution reach

Benzinga - 7 months ago

Precipio (NASDAQ: PRPO) shares are trading higher on Thursday. The company announced it entered into an agreement with ADS Biotec to distribute its FDA-authorized COVID-19 serology antibody te...

GlobeNewsWire - 7 months ago

Test received FDA EUA; commercialization begins Test received FDA EUA; commercialization begins

GlobeNewsWire - 7 months ago

NEW HAVEN, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced its preliminary unaudited revenues for its pathology services i...

GlobeNewsWire - 8 months ago

NEW HAVEN, Conn., July 01, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that it has regained compliance with the Nasdaq listing require...

GlobeNewsWire - 8 months ago

Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters

Seeking Alpha - 9 months ago

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume Precipio Pathology Sales Performance Metrics Demonstrate Growth in Cus...

GlobeNewsWire - 9 months ago

Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST

GlobeNewsWire - 11 months ago

Oncology Practices Improve Patient care and Increase Revenue & Profit Oncology Practices Improve Patient care and Increase Revenue & Profit

GlobeNewsWire - 11 months ago

Letter to the Shareholders from the CEO Letter to the Shareholders from the CEO

GlobeNewsWire - 11 months ago

Customer base and sales team transition to Precipio, Doubling Revenues Customer base and sales team transition to Precipio, Doubling Revenues

GlobeNewsWire - 1 year ago

Groundbreaking clinical and economic impact to be generated

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it is in advanced discussions with Poplar Healthcar...

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Jan. 28, 2020 (GLOBE NEWSWIRE) -- The management team of Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), would like to provide an explanation on the recent...

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Jan. 15, 2020 (GLOBE NEWSWIRE) -- The management team of Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), would like to provide several clarification points...

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that on Monday, January 20th at 5pm it will conduct a sharehold...

Seeking Alpha - 1 year ago

Precipio's (PRPO) CEO Ilan Danieli on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Following completion of a successful validation testing, laboratory set to launch assay Following completion of a successful validation testing, laboratory set to launch assay

GlobeNewsWire - 1 year ago

 Orders expected from several major labs both domestically and internationally

GlobeNewsWire - 1 year ago

First cases already diagnosed and reported by Penn expert pathologists First cases already diagnosed and reported by Penn expert pathologists

Seeking Alpha - 1 year ago

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2019 Results - Earnings Call Transcript

About PRPO

Precipio, a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratorie... [Read more...]

Industry
Diagnostics & Research
CEO
Paul Kinnon
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
PRPO
Full Company Profile

Financial Performance

In 2019, Precipio's revenue was $3.13 million, an increase of 9.18% compared to the previous year's $2.86 million. Losses were -$13.24 million, -15.62% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Precipio is 4.15, which is an increase of 90.37% from the latest price.

Price Target
$4.15
(90.37% upside)